FDA
-
-
-
-
-
-
-
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) Reports Positive Interim Data for LX1001
-
-
-
-
-
-
-
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
-
-
-
-
-
-
-
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

